Dabur India Ltd
Dabur India is one of the leading fast moving consumer goods (FMCG) players dealing in consumer care and food products.(Source : 202003 Annual Report Page No:280)
- Market Cap ₹ 97,551 Cr.
- Current Price ₹ 550
- High / Low ₹ 611 / 504
- Stock P/E 56.3
- Book Value ₹ 53.5
- Dividend Yield 0.94 %
- ROCE 22.7 %
- ROE 19.5 %
- Face Value ₹ 1.00
Pros
- Company has been maintaining a healthy dividend payout of 52.1%
Cons
- Stock is trading at 10.2 times its book value
- The company has delivered a poor sales growth of 8.35% over past five years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: FMCG Industry: Personal Care - Indian
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
5,294 | 6,140 | 7,058 | 7,795 | 7,780 | 7,614 | 7,722 | 8,515 | 8,685 | 9,562 | 10,889 | 11,530 | 12,055 | |
4,401 | 5,148 | 5,897 | 6,475 | 6,261 | 6,102 | 6,104 | 6,775 | 6,892 | 7,560 | 8,637 | 9,367 | 9,771 | |
Operating Profit | 893 | 992 | 1,162 | 1,320 | 1,518 | 1,512 | 1,617 | 1,740 | 1,792 | 2,002 | 2,252 | 2,162 | 2,284 |
OPM % | 17% | 16% | 16% | 17% | 20% | 20% | 21% | 20% | 21% | 21% | 21% | 19% | 19% |
55 | 100 | 126 | 154 | 217 | 296 | 291 | 222 | 205 | 325 | 308 | 445 | 448 | |
Interest | 54 | 59 | 54 | 40 | 48 | 54 | 53 | 60 | 50 | 31 | 39 | 78 | 103 |
Depreciation | 103 | 85 | 97 | 115 | 133 | 143 | 162 | 177 | 220 | 240 | 253 | 311 | 368 |
Profit before tax | 790 | 948 | 1,136 | 1,319 | 1,554 | 1,611 | 1,693 | 1,725 | 1,728 | 2,056 | 2,269 | 2,219 | 2,261 |
Tax % | 19% | 19% | 19% | 19% | 19% | 21% | 20% | 16% | 16% | 18% | 23% | 23% | |
644 | 766 | 916 | 1,068 | 1,254 | 1,280 | 1,358 | 1,446 | 1,448 | 1,695 | 1,742 | 1,701 | 1,733 | |
EPS in Rs | 3.70 | 4.38 | 5.24 | 6.07 | 7.11 | 7.25 | 7.69 | 8.17 | 8.18 | 9.58 | 9.84 | 9.64 | 9.92 |
Dividend Payout % | 38% | 34% | 33% | 33% | 32% | 31% | 81% | 34% | 37% | 50% | 53% | 54% |
Compounded Sales Growth | |
---|---|
10 Years: | 7% |
5 Years: | 8% |
3 Years: | 10% |
TTM: | 7% |
Compounded Profit Growth | |
---|---|
10 Years: | 8% |
5 Years: | 4% |
3 Years: | 4% |
TTM: | -3% |
Stock Price CAGR | |
---|---|
10 Years: | 13% |
5 Years: | 6% |
3 Years: | 3% |
1 Year: | -7% |
Return on Equity | |
---|---|
10 Years: | 26% |
5 Years: | 23% |
3 Years: | 22% |
Last Year: | 19% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 174 | 174 | 174 | 176 | 176 | 176 | 176 | 177 | 177 | 177 | 177 | 177 | 177 |
Reserves | 1,543 | 1,921 | 2,482 | 3,178 | 3,995 | 4,671 | 5,530 | 5,455 | 6,429 | 7,487 | 8,205 | 8,796 | 9,310 |
1,068 | 1,151 | 708 | 734 | 805 | 975 | 938 | 699 | 522 | 509 | 1,030 | 1,174 | 1,489 | |
1,415 | 1,462 | 1,948 | 2,019 | 1,956 | 1,910 | 2,058 | 2,106 | 2,209 | 2,661 | 2,872 | 3,505 | 3,791 | |
Total Liabilities | 4,200 | 4,709 | 5,312 | 6,106 | 6,932 | 7,732 | 8,702 | 8,437 | 9,337 | 10,833 | 12,284 | 13,652 | 14,767 |
1,641 | 1,582 | 1,767 | 1,877 | 1,667 | 1,958 | 2,028 | 1,969 | 2,253 | 2,243 | 2,308 | 3,579 | 3,558 | |
CWIP | 27 | 93 | 22 | 50 | 45 | 42 | 42 | 64 | 147 | 147 | 168 | 175 | 259 |
Investments | 483 | 929 | 1,076 | 1,813 | 2,691 | 3,240 | 3,805 | 3,359 | 2,800 | 4,160 | 6,220 | 6,265 | 6,922 |
2,050 | 2,105 | 2,447 | 2,365 | 2,529 | 2,492 | 2,827 | 3,045 | 4,137 | 4,283 | 3,589 | 3,633 | 4,029 | |
Total Assets | 4,200 | 4,709 | 5,312 | 6,106 | 6,932 | 7,732 | 8,702 | 8,437 | 9,337 | 10,833 | 12,284 | 13,652 | 14,767 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
597 | 870 | 1,098 | 1,047 | 1,187 | 1,227 | 1,092 | 1,499 | 1,614 | 2,115 | 1,802 | 1,488 | |
-260 | -622 | -104 | -876 | -730 | -807 | -541 | 338 | -517 | -1,404 | -1,273 | -583 | |
-198 | -234 | -804 | -417 | -374 | -339 | -577 | -1,888 | -1,043 | -613 | -490 | -1,035 | |
Net Cash Flow | 138 | 13 | 190 | -245 | 82 | 81 | -27 | -51 | 54 | 97 | 38 | -130 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 32 | 29 | 35 | 33 | 38 | 31 | 33 | 36 | 34 | 21 | 22 | 27 |
Inventory Days | 154 | 144 | 150 | 136 | 150 | 153 | 169 | 154 | 164 | 178 | 169 | 158 |
Days Payable | 89 | 122 | 169 | 153 | 182 | 181 | 190 | 172 | 176 | 197 | 178 | 171 |
Cash Conversion Cycle | 97 | 51 | 16 | 16 | 6 | 3 | 13 | 17 | 22 | 3 | 12 | 14 |
Working Capital Days | 22 | 12 | 2 | 7 | 21 | 14 | 21 | 16 | 22 | 5 | 7 | 10 |
ROCE % | 32% | 33% | 35% | 36% | 35% | 31% | 28% | 28% | 28% | 27% | 27% | 23% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Credit Rating
30 Nov - Of re-affirmation of Credit Rating under Regulation 30 of SEBI (LODR) Regulations, 2015.
-
Announcement under Regulation 30 (LODR)-Investor Presentation
20 Nov - Of schedule of Analyst/ Institutional Investors meet and copy of presentation to be shared with investors at 26th CITIC CLSA India Forum 2023 to be …
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
18 Nov - Enclose copies each of the Financial Express (English Daily) and Jansatta (Hindi Daily), both dated 18.11.2023 in which intimation of Postal Ballot Notice for seeking …
- Shareholder Meeting / Postal Ballot-Notice of Postal Ballot 17 Nov
- Submission Of Information Under Regulation 30 Of SEBI (LODR) Regulations, 2015- Update On Letter Dated 18.10.2023 15 Nov
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from nse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Concalls
-
Nov 2023Transcript PPT
-
Nov 2023TranscriptNotesPPT
-
Nov 2023TranscriptNotesPPT
-
Sep 2023TranscriptNotesPPT
-
Sep 2023TranscriptNotesPPT
-
Aug 2023TranscriptNotesPPT
-
Aug 2023Transcript PPT
-
Aug 2023TranscriptNotesPPT
-
May 2023Transcript PPT
-
May 2023TranscriptNotesPPT
-
Feb 2023Transcript PPT
-
Oct 2022Transcript PPT
-
Aug 2022Transcript PPT
-
Aug 2022TranscriptNotesPPT
-
Jun 2022Transcript PPT
-
May 2022TranscriptNotesPPT
-
Feb 2022Transcript PPT
-
Nov 2021Transcript PPT
-
Aug 2021Transcript PPT
-
Aug 2021TranscriptNotesPPT
-
May 2021Transcript PPT
-
May 2021TranscriptNotesPPT
-
Feb 2021Transcript PPT
-
Nov 2020Transcript PPT
-
Sep 2020Transcript PPT
-
Jul 2020Transcript PPT
-
May 2020TranscriptNotesPPT
-
Feb 2020Transcript PPT
-
Nov 2019Transcript PPT
-
Nov 2019TranscriptNotesPPT
-
Sep 2019TranscriptNotesPPT
-
Aug 2019Transcript PPT
-
Jul 2019TranscriptNotesPPT
-
May 2019Transcript PPT
-
Feb 2019Transcript PPT
-
Nov 2018Transcript PPT
-
Aug 2018TranscriptNotesPPT
-
Aug 2018Transcript PPT
-
Jul 2018TranscriptNotesPPT
-
May 2018TranscriptNotesPPT
-
Feb 2018TranscriptNotesPPT
-
Jan 2018TranscriptNotesPPT
-
Nov 2017Transcript PPT
-
Sep 2017Transcript PPT
-
Aug 2017TranscriptNotesPPT
-
May 2017Transcript PPT
-
Feb 2017TranscriptPPT
-
Nov 2016TranscriptPPT
-
Jul 2016TranscriptNotesPPT
-
Jun 2016TranscriptNotesPPT
-
May 2016Transcript PPT
-
Feb 2016Transcript PPT
Dabur India Limited is the fourth largest FMCG Company in India and the world’s largest Ayurvedic and Natural Health Care Company with a portfolio of over 250 Herbal/Ayurvedic products.[1]